Barclays PLC Purchases 33,185 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Barclays PLC grew its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 390.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 41,684 shares of the company's stock after acquiring an additional 33,185 shares during the quarter. Barclays PLC owned 0.14% of Dianthus Therapeutics worth $1,141,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Quest Partners LLC boosted its holdings in Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company's stock worth $31,000 after purchasing an additional 1,124 shares during the last quarter. Fred Alger Management LLC grew its holdings in shares of Dianthus Therapeutics by 52.5% in the 3rd quarter. Fred Alger Management LLC now owns 9,633 shares of the company's stock valued at $264,000 after acquiring an additional 3,316 shares in the last quarter. SG Americas Securities LLC increased its position in shares of Dianthus Therapeutics by 104.0% in the third quarter. SG Americas Securities LLC now owns 8,839 shares of the company's stock valued at $242,000 after acquiring an additional 4,506 shares during the last quarter. MetLife Investment Management LLC raised its holdings in Dianthus Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 13,939 shares of the company's stock worth $382,000 after acquiring an additional 7,854 shares in the last quarter. Finally, American Century Companies Inc. boosted its position in Dianthus Therapeutics by 38.6% during the second quarter. American Century Companies Inc. now owns 30,432 shares of the company's stock valued at $788,000 after purchasing an additional 8,473 shares during the last quarter. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Stock Performance

NASDAQ:DNTH traded down $3.16 during mid-day trading on Tuesday, reaching $19.88. 342,653 shares of the company's stock were exchanged, compared to its average volume of 321,419. Dianthus Therapeutics, Inc. has a one year low of $10.65 and a one year high of $33.77. The business's fifty day simple moving average is $24.38 and its two-hundred day simple moving average is $26.60. The firm has a market capitalization of $588.39 million, a PE ratio of -7.95 and a beta of 1.74.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.07 million. As a group, equities research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on DNTH. Raymond James raised Dianthus Therapeutics to a "moderate buy" rating in a research report on Thursday, December 12th. HC Wainwright reiterated a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Oppenheimer boosted their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an "outperform" rating in a research note on Monday, November 11th. Finally, TD Cowen started coverage on shares of Dianthus Therapeutics in a research note on Friday, December 20th. They issued a "buy" rating for the company. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Dianthus Therapeutics has a consensus rating of "Buy" and a consensus price target of $46.43.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.